Author:
Obolski Uri,Stensrud Mats J,Nevo Daniel
Reference8 articles.
1. Safety and durable immunogenicity of the TV005 tetravalent dengue vaccine, across serotypes and age groups, in dengue-endemic Bangladesh: a randomised, controlled trial;Walsh;Lancet Infect Dis,2023
2. Stensrud MJ, Nevo D, Obolski U. Distinguishing immunologic and behavioral effects of vaccination. Epidemiology (in press).
3. Efficacy of a tetravalent dengue vaccine in healthy children and adolescents;Biswal;N Engl J Med,2019
4. Efficacy of a tetravalent dengue vaccine in healthy children aged 4–16 years: a randomised, placebo-controlled, phase 3 trial;Biswal;Lancet,2020
5. Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines: umbrella review of systematic reviews;Villa;J Am Dent Assoc,2020